Skip to main content

New application note shows how to rapidly assess CAR T-cell strategies for multiple myeloma

We are excited to announce that our latest application note, Rapid assessment of CAR T-cell strategies for multiple myeloma with the z-Movi® Cell Avidity Analyzer, is available to download. In this application note, we highlight cell avidity and in vivo experiments performed in collaboration with the teams of Dr. Eric Smith (Dana-Farber Cancer Institute) and Prof.
Carlos de Larrea (Hospital Clínic Barcelona) and show how you can use the z-Movi® to:

  • Rapidly identify new, effective CAR T-cell therapy candidates for multiple myeloma through cell-avidity measurements.
  • Predict in vivo outcomes by comparing cell-avidity outcomes between CAR T-cell populations.
  •  Retrieve high-throughput data from different CAR T-cell populations within 24 hours.

Download a copy of the application note here to discover how you can assess the avidity of your cells to explore and validate CAR T-cell functionality and obtain predictive, reproducible, and rapid results at the single-cell level without compromising cell viability.

Feel free to contact us if you want more information about the z-Movi® or our other instruments for single-molecule or single-cell research.

Close Menu

For pricing, reach out to your application scientist or account manager

Open Email

Fill in our contact form, we will reach out to you!

Please include ‘Lakeview data analysis price inquiry’ in the Message box

Contact Us

Join our newsletter

Get exclusive news on the latest publications, product developments, events and breakthrough science.

By submitting the form you agree to LUMICKS' privacy policy. You can revoke your consent at any time.

Download our webinar recording:


Download our Cell Therapy (CAR-T, TCR, NK) applications deck